Psoriatic Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been prescribed Rinvoq™ (upadacitinib) on or after January 1, 2024
- You are 18 years of age or older at the time of joining the study
- You are willing to give your consent to take part in the study
Who may not be able to join:
- You have any level of cognitive difficulty that would make it hard to answer questions over the phone
- You are currently taking part in a Phase I, II, or III clinical trial
- You have a life expectancy of less than 1 month
- You do not have a working phone number that can be contacted
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Inês Ribeiro Vaz, PharmD, MPH, PhD, Universidade do Porto
Phone: + 351220426952
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.